Default company panoramic image
Fa140b46 56b6 4e76 8f96 3b017c493264

Tolerion, Inc.

Tolerion has a novel, patented drug in Phase 2 that has potential for being the first disease modifying therapy in type 1 diabetes.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Portola Valley, CA, USA
  • Currency USD
  • Founded June 2012
  • Employees 0
  • Website

Company Summary

Based on our novel platform for treating autoimmune disease, we are developing TOL-3021, the first disease-modifying therapy for type 1 diabetes (T1D). We completed a Ph 2 study in T1D patients showing that, relative to placebo, TOL-3021 significantly improved C-peptide levels, an FDA-approvable biomarker of pancreatic insulin production and beta cell mass. As no disease-modifying drugs exist for T1D, the sales potential for TOL-3021 is large.


  • Default avatar
    Nigel Ray